This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2011 Aug 1;10(8):563-4.

doi: 10.1038/nrd3527.

PI3K pathway inhibitors approach junction

PMID: 21804582
DOI: 10.1038/nrd3527

PI3K pathway inhibitors approach junction

David Holmes. Nat Rev Drug Discov. 2011.

. 2011 Aug 1;10(8):563-4.

doi: 10.1038/nrd3527.

Author

PMID: 21804582
DOI: 10.1038/nrd3527

No abstract available

PubMed Disclaimer

Similar articles

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM, Furet P, Stauffer F. Maira SM, et al. Future Med Chem. 2009 Apr;1(1):137-55. doi: 10.4155/fmc.09.5. Future Med Chem. 2009. PMID: 21426073 Review.
[PI3K-AKT-mTOR pathway inhibitors].
Cortot A, Armand JP, Soria JC. Cortot A, et al. Bull Cancer. 2006 Jan;93(1):19-26. Bull Cancer. 2006. PMID: 16455502 Review. French.
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q, Lui VW, Yeo W. Zhou Q, et al. Future Oncol. 2011 Oct;7(10):1149-67. doi: 10.2217/fon.11.95. Future Oncol. 2011. PMID: 21992728 Review.
[PI3K inhibitor].
Yano S, Takeuchi S, Yamada T, Mouri H, Yamashita K, Ohtsubo K, Yasumoto K. Yano S, et al. Gan To Kagaku Ryoho. 2011 Jan;38(1):23-6. Gan To Kagaku Ryoho. 2011. PMID: 21368457 Japanese.
Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
Bartlett JM. Bartlett JM. Clin Breast Cancer. 2010 Nov;10 Suppl 3:S86-95. doi: 10.3816/CBC.2010.s.017. Clin Breast Cancer. 2010. PMID: 21115427 Review.

See all similar articles

Cited by

Sox2: regulation of expression and contribution to brain tumors.
Mansouri S, Nejad R, Karabork M, Ekinci C, Solaroglu I, Aldape KD, Zadeh G. Mansouri S, et al. CNS Oncol. 2016 Jul;5(3):159-73. doi: 10.2217/cns-2016-0001. Epub 2016 May 27. CNS Oncol. 2016. PMID: 27230973 Free PMC article. Review.
Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter.
Whitehead MA, Bombardieri M, Pitzalis C, Vanhaesebroeck B. Whitehead MA, et al. Biochem J. 2012 May 1;443(3):857-67. doi: 10.1042/BJ20112214. Biochem J. 2012. PMID: 22375552 Free PMC article.
Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study.
Deipolyi AR, Riedl CC, Bromberg J, Chandarlapaty S, Klebanoff CA, Sofocleous CT, Yarmohammadi H, Brody LA, Boas FE, Ziv E. Deipolyi AR, et al. J Vasc Interv Radiol. 2018 Sep;29(9):1226-1235. doi: 10.1016/j.jvir.2018.04.018. Epub 2018 Aug 3. J Vasc Interv Radiol. 2018. PMID: 30078647 Free PMC article.
Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.
Silva IT, Geller FC, Persich L, Dudek SE, Lang KL, Caro MS, Durán FJ, Schenkel EP, Ludwig S, Simões CM. Silva IT, et al. Invest New Drugs. 2016 Apr;34(2):139-48. doi: 10.1007/s10637-015-0317-4. Epub 2016 Jan 16. Invest New Drugs. 2016. PMID: 26780083
Knockdown of GSG2 inhibits the development and progression of non-small cell lung cancer in vitro and in vivo.
Zhang F, Qiu B, Ji Y, Zhang H, Song P, Sun N, Zhao L, Lv F, Yin L, Gao Y, Xue Q, Gao S, He J. Zhang F, et al. Cell Cycle. 2023 Jan;22(2):153-164. doi: 10.1080/15384101.2022.2110441. Epub 2022 Aug 16. Cell Cycle. 2023. PMID: 35972887 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database